Skip to main content
Optipharm.CO.,LTD logo

Optipharm.CO.,LTD — Investor Relations & Filings

Ticker · 153710 ISIN · KR7153710009 KO Professional, scientific and technical activities
Open in API
Filings indexed 177 across all filing types
Latest filing 2021-12-07 Major Shareholding Noti…
Country KR South Korea
Listing KO 153710

About Optipharm.CO.,LTD

https://www.optipharm.co.kr

Optipharm is a biomedical company specializing in animal health solutions and advanced biotherapeutics. The company's core activities encompass animal disease diagnosis, the development and sale of veterinary pharmaceuticals, and the creation of bacteriophage-based treatments. A key focus is on preventative medicine, including the research and development of Virus-Like Particle (VLP) vaccines and a nanoparticle-based vaccine for Foot-and-Mouth Disease. In the biomedical sector, Optipharm is advancing xenotransplantation through its 'Medipig' platform for developing xenogeneic organs and tissues. The company also produces transgenic animal models for research and develops cell therapy products using animal stem cells, with a long-term strategy to transition its innovations to human medicine.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the shareholding status, changes in ownership, and the purpose of holding shares by a major shareholder (Easy Holdings) and its special related parties in the company Optipharm. This document type is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2021-12-07 Korean
기타경영사항(특허권취득)(자율공시)
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure from a Korean company (Optipharm) regarding the acquisition of patents. It is titled 'Other Management Matters (Patent Acquisition) (Voluntary Disclosure)'. Since it is a specific regulatory announcement regarding corporate developments that does not fit into financial reporting, dividend, or shareholder meeting categories, it falls under the 'Regulatory Filings' (RNS) category as a general corporate disclosure.
2021-12-01 Korean
대표이사변경
Board/Management Information Classification · 1% confidence The document is a formal announcement regarding the change of the company's CEO (Representative Director). It details the 'before' and 'after' names, the reason for the change (resignation), the date of the board resolution, and the profile of the new CEO. This fits perfectly into the 'Board/Management Information' category.
2021-11-30 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically a '정정신고' (Correction Report). It details changes to previously granted stock options, including the number of recipients and the total number of shares involved. This type of filing is a standard regulatory disclosure regarding corporate capital structure and incentive plans, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes).
2021-11-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (purchases) made by a director (Kim Hyun-il) of the company Optipharm. This type of filing is a standard regulatory disclosure for insider trading or director's dealings in the Korean market.
2021-11-26 Korean
분기보고서 (2021.09)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for the company 'Optipharm' (주식회사 옵티팜) covering the period from January 1, 2021, to September 30, 2021. It contains detailed financial information, business descriptions, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-11-12 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.